Cancer Institute A national cancer institute
designated cancer center

James L. Zehnder, M.D.

Publication Details

  • Comprehensive and Efficient HBB Mutation Analysis for Detection of beta-Hemoglobinopathies in a Pan-Ethnic Population AMERICAN JOURNAL OF CLINICAL PATHOLOGY Chan, O. T., Westover, K. D., Dietz, L., Zehnder, J. L., Schrijver, I. 2010; 133 (5): 700-707

    Abstract:

    Current methods that assay hemoglobin beta-globin chain variants can have limited clinical sensitivity when applied techniques identify only a predefined panel of mutations. Even sequence-based assays may be limited depending on which gene regions are investigated. We sought to develop a clinically practical yet inclusive molecular assay to identify beta-globin mutations in multicultural populations. We highlight the beta-globin mutation detection assay (beta-GMDA), an extensive gene sequencing assay. The polymerase chain reaction (PCR) primers are located to encompass virtually all hemoglobin beta locus (HBB) mutations. In addition, this assay is able to detect, by gap PCR, a common large deletion (Delta619 base pair), which would be missed by sequencing alone. We describe our 5-year experience with the beta-GMDA and indicate its capability for detecting homozygous, heterozygous, and compound heterozygous sequence changes, including previously unknown HBB variants. The beta-GMDA offers superior sensitivity and ease of use with comprehensive detection of HBB mutations that result in beta-globin chain variants.

    View details for DOI 10.1309/AJCP7HQ2KWGHECIO

    View details for Web of Science ID 000277476500004

    View details for PubMedID 20395516

Stanford Medicine Resources:

Footer Links: